DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AJANTA PHARMA LIMITED (AJANTPHARM) share price today?

AJANTA PHARMA LIMITED (AJANTPHARM) is trading at ₹3,419.4 on the NSE, down 0.97% on the day. Source: DocStoX.

What is the PE ratio of AJANTA PHARMA LIMITED?

AJANTA PHARMA LIMITED has a price-to-earnings (PE) ratio of 40.5 in the Healthcare sector.

What is the market capitalisation of AJANTA PHARMA LIMITED?

AJANTA PHARMA LIMITED has a market capitalisation of approximately ₹42,731 crore.

AJANTA PHARMA LIMITED

AJANTPHARM·NSE·Healthcare

₹3,419.40▼ -33.40 (-0.97%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY MIDCAP 150NIFTY PHARMA

Day₹3341.10

₹3454.00

52W₹2330

₹350793%

Open

₹3454.00

High

₹3454.00

Low

₹3341.10

Prev Close

₹3452.80

Volume

93.4K

VWAP

₹3399.66

Snapshot

Key fundamentals

Market Cap

₹42,731 Cr

P/E Ratio

40.46Expensive

P/B Ratio

9.24

EPS

₹84.52

Book Value

₹362.00

ROE

27.10%Strong

ROCE

35.00%Efficient

Dividend Yield

0.85%

Debt / Equity

0.06Low

Face Value

₹2.00

52W High

₹3506.90

52W Low

₹2329.90

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹689

▼ 79.8%downside

Trading at ₹3,419 — 80% above our estimate

BearFair valueBull

₹586₹689₹830

/100

Business quality — Solid

Growth 70Profitability 98Efficiency 50Valuation 60

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (27%)
Capital is working hard (ROCE 35%)
Profit growing 22% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

27% ROE fading to 12% over ~10 yrs, on ₹362 book

₹650

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹830

Analyst target

No analyst coverage

—

Blended fair value₹689

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (27%)
Capital is working hard (ROCE 35%)
Profit growing 22% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

40.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

27.1%Strong

Above 15% is considered healthy for Indian equities

ROCE

35.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.06Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹42,731 Cr

P/B

9.24

EPS

₹84.52

Div Yield

0.85%

What changed

Recent changes

Foreign investors-0.6% stake last quarter
Domestic institutions+3.4% stake last quarter
Promoters-2.76% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 40.5×

Growth

Steady

+13% rev CAGR

Profitability

Excellent

27.1% ROE

Financial health

Rock solid

D/E 0.06

Momentum

N/A

No technicals

Today

Trading activity

Delivery %46.3%

Turnover₹3175.65L Cr

Trades16,925

VWAP₹3399.66

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+13.4%

+13.5%

10Y

+12.0%

Profit

+21.6%

+10.1%

10Y

+9.8%

EPS

+22.6%

+10.9%

10Y

+10.4%

Profile

Pros

Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
Company has been maintaining a healthy dividend payout of 50.1%

Watch-outs

Cons

Stock is trading at 9.24 times its book value

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 2.76 pts; foreign investors sold 0.58 pts; domestic institutions added 3.44 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

63%

Promoter

Promoters

63.5%-2.76

Public

7.0%-0.11

FII / FPI

7.7%-0.58

DII

21.8%+3.44

Quarterly trend

Ownership over time

Q1 FY27

Promoter63.49%

FII7.68%

DII21.80%

Public7.03%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).